Aurora Cannabis at 0.97x Sales Looks Cheap-If Europe's Growth Can Keep Compounding

Aurora's valuation looks muted relative to its latest revenue

Aurora currently has a $382.76 million market cap after a quarter that produced $67.6 million net revenue - about 0.97x trailing quarterly sales. Put another way, investors are paying less than one year of the most recent quarter's revenue for a company that still holds $149.1 million of cash, cash equivalents and short-term investments with no debt. On a simple annualized basis, that works out to roughly 1.4x sales, which is low for a business that is no longer under leverage pressure.

The discount likely reflects old baggage. Cannabis still carries reputational risk, and Aurora's history gives investors reason to question headline growth. But the more important data point is the 17% YoY increase in international medical cannabis net revenue in the latest quarter. That supports the idea that the better part of the business is the regulated medical franchise, especially in Europe.

Europe and Safari are the main reason the valuation gap could close

Fiscal 2026 already points to a better business mix

For full fiscal 2026, Aurora reported record annual global medical cannabis net revenue of $288.6 million, up 18% year over year, and record annual adjusted EBITDA of $53.8 million, representing 32% YoY growth. The fact that EBITDA grew faster than revenue suggests the mix is improving, not just the top line.

The third quarter shows the same pattern at a more granular level. Medical revenue reached a record $76.2 million, adjusted EBITDA was $18.5 million, and free cash flow was $15.5 million. That does not prove the thesis on its own, but it does show growth translating into profitability and cash generation rather than pure volume.

Safari strengthens the European supply base

Aurora's acquisition of Safari Flower Company matters because it adds EU-GMP capacity where the better economics already exist. Aurora said the deal added Critical Capacity to Serve Growing Profitable International Markets, and Safari also received Three-Year EU-GMP Certification. In medical cannabis, certified local supply can make distribution and customer onboarding more reliable.

Aurora has also reinforced that commitment with localized websites for key European markets including Germany, the UK, and Poland. That alone does not prove commercial traction, but it does signal an effort to make the brand more accessible to healthcare professionals, partners, and distributors.

What would validate the rerating thesis

The bullish case does not require Canada to suddenly become a premium market. It mainly requires Europe to keep growing while Safari reduces supply constraints. The clearest watchpoints are:

• sustained double-digit international medical growth
• medical revenue continuing to support EBITDA and free cash flow
• Safari capacity translating into broader commercial progress

Why the stock still looks undervalued - and what could change that view

At present, the market still seems to be treating Aurora like a legacy cannabis stock instead of a company with a scaling European medical franchise. The shares sit in the middle of its 52-week range and above its 200-day simple moving average, and the company remains debt-free with ample cash. That combination supports the view that the main question is investor perception, not immediate financial stress.

The analyst community is not ignoring that possibility. Aurora has 3 Buy ratings, with an average 12-month target of C$7.17 versus a recent price of C$4.18, implying about 71.45% upside. That is not a prediction of fundamentals; it is evidence that some analysts see more value than the stock is currently attracting.

The clearest path to a higher valuation is straightforward: international medical growth needs to keep compounding, and the company needs to keep showing that expansion is improving margins and cash flow. If that keeps happening, today's sales multiple may look too low for what is already a better-quality business than the market gives it credit for.